{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T13:23:08Z","timestamp":1784380988574,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-43949-z","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T09:03:14Z","timestamp":1773478994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterizing persistent Post-COVID-19 vaccination symptoms using MedDRA system organ class and preferred term classifications"],"prefix":"10.1038","volume":"16","author":[{"given":"Akinori","family":"Fujisawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafuko","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Miyokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"issue":"9","key":"43949_CR1","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","volume":"22","author":"OJ Watson","year":"2022","unstructured":"Watson, O. J. et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet. Infect. Dis. 22 (9), 1293\u20131302. https:\/\/doi.org\/10.1016\/S1473-3099(22)00320-6 (2022).","journal-title":"Lancet. Infect. Dis"},{"key":"43949_CR2","doi-asserted-by":"publisher","first-page":"873596","DOI":"10.3389\/fpubh.2022.873596","volume":"10","author":"K Rahmani","year":"2022","unstructured":"Rahmani, K. et al. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. Front. Public. Health. 10, 873596. https:\/\/doi.org\/10.3389\/fpubh.2022.873596 (2022).","journal-title":"Front. Public. Health"},{"key":"43949_CR3","doi-asserted-by":"publisher","first-page":"100928","DOI":"10.1016\/j.lanwpc.2023.100928","volume":"40","author":"B Liu","year":"2023","unstructured":"Liu, B. et al. Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study. Lancet Reg. Health West. Pac. 40, 100928. https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100928 (2023).","journal-title":"Lancet Reg. Health West. Pac."},{"issue":"4","key":"43949_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40264-023-01290-8","volume":"46","author":"V Bauchau","year":"2023","unstructured":"Bauchau, V., Davis, K., Frise, S., Jouquelet-Royer, C. & Wilkins, J. Real-World Monitoring of COVID-19 Vaccines: An Industry Expert View on the Successes, Challenges, and Future Opportunities. Drug Saf. 46 (4), 327\u2013333. https:\/\/doi.org\/10.1007\/s40264-023-01290-8 (2023).","journal-title":"Drug Saf."},{"issue":"25","key":"43949_CR5","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1016\/j.vaccine.2023.04.055","volume":"41","author":"SB Black","year":"2023","unstructured":"Black, S. B., Chandler, R. E., Edwards, K. M. & Sturkenboom, M. C. J. M. Assessing vaccine safety during a pandemic: Recent experience and lessons learned for the future. Vaccine 41 (25), 3790\u20133795. https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.055 (2023).","journal-title":"Vaccine"},{"issue":"3","key":"43949_CR6","doi-asserted-by":"publisher","first-page":"e014544","DOI":"10.1136\/bmjgh-2023-014544","volume":"9","author":"RE Chandler","year":"2024","unstructured":"Chandler, R. E. et al. Collaboration within the global vaccine safety surveillance ecosystem during the COVID-19 pandemic: lessons learnt and key recommendations from the COVAX Vaccine Safety Working Group. BMJ Glob Health. 9 (3), e014544. https:\/\/doi.org\/10.1136\/bmjgh-2023-014544 (2024).","journal-title":"BMJ Glob Health"},{"issue":"1","key":"43949_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/d41573-022-00178-z","volume":"22","author":"A Kiazand","year":"2023","unstructured":"Kiazand, A. et al. Pandemic vaccines: a formidable challenge for pharmacovigilance. Nat. Rev. Drug Discov. 22 (1), 1\u20132. https:\/\/doi.org\/10.1038\/d41573-022-00178-z (2023).","journal-title":"Nat. Rev. Drug Discov"},{"issue":"9","key":"43949_CR8","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.cjca.2024.03.016","volume":"40","author":"MA McDonald","year":"2024","unstructured":"McDonald, M. A. et al. Myocarditis and Pericarditis After mRNA COVID-19 Vaccination: 2024 Status and Management Update. Can. J. Cardiol. 40 (9), 1536\u20131540. https:\/\/doi.org\/10.1016\/j.cjca.2024.03.016 (2024).","journal-title":"Can. J. Cardiol."},{"key":"43949_CR9","doi-asserted-by":"publisher","unstructured":"Jain, S. S. et al. Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV) multicenter study. eClinicalMedicine 76 https:\/\/doi.org\/10.1016\/j.eclinm.2024.102809 (2024).","DOI":"10.1016\/j.eclinm.2024.102809"},{"issue":"16","key":"43949_CR10","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1001\/jama.2024.16380","volume":"332","author":"L Semenzato","year":"2024","unstructured":"Semenzato, L. et al. Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies. JAMA 332 (16), 1367\u20131377. https:\/\/doi.org\/10.1001\/jama.2024.16380 (2024).","journal-title":"JAMA"},{"key":"43949_CR11","doi-asserted-by":"publisher","first-page":"100485","DOI":"10.1016\/j.jvacx.2024.100485","volume":"18","author":"PA ShamaeiZadeh","year":"2024","unstructured":"ShamaeiZadeh, P. A., Jaimes, C. V., Knoll, M. D., Espi\u00e9, E. & Chandler, R. E. Landscape review of active vaccine safety surveillance activities for COVID-19 vaccines globally. Vaccine: X. 18, 100485. https:\/\/doi.org\/10.1016\/j.jvacx.2024.100485 (2024).","journal-title":"Vaccine: X"},{"key":"43949_CR12","doi-asserted-by":"publisher","first-page":"q488","DOI":"10.1136\/bmj.q488","volume":"384","author":"J Wise","year":"2024","unstructured":"Wise, J. Covid-19: Two rare vaccine side effects detected in large global study. BMJ 384, q488. https:\/\/doi.org\/10.1136\/bmj.q488 (2024).","journal-title":"BMJ"},{"issue":"1","key":"43949_CR13","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1186\/s12879-024-09969-8","volume":"24","author":"J Domen","year":"2024","unstructured":"Domen, J. et al. Predictors of moderate-to-severe side-effects following COVID-19 mRNA booster vaccination: a prospective cohort study among primary health care providers in Belgium. BMC Infect. Dis. 24 (1), 1135. https:\/\/doi.org\/10.1186\/s12879-024-09969-8 (2024).","journal-title":"BMC Infect. Dis."},{"key":"43949_CR14","doi-asserted-by":"publisher","unstructured":"Bhattacharjee, B. et al. Immunological and Antigenic Signatures Associated with Chronic Illnesses after COVID-19 Vaccination. [PREPRINT]. https:\/\/doi.org\/10.1101\/2025.02.18.25322379 (2025).","DOI":"10.1101\/2025.02.18.25322379"},{"issue":"12","key":"43949_CR15","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.3390\/vaccines12121378","volume":"12","author":"B Platschek","year":"2024","unstructured":"Platschek, B. & Boege, F. The Post-Acute COVID-19-Vaccination Syndrome in the Light of Pharmacovigilance. Vaccines 12 (12), 1378. https:\/\/doi.org\/10.3390\/vaccines12121378 (2024).","journal-title":"Vaccines"},{"issue":"7","key":"43949_CR16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3390\/vaccines12070790","volume":"12","author":"AK Mundorf","year":"2024","unstructured":"Mundorf, A. K. et al. Clinical and Diagnostic Features of Post-Acute COVID-19 Vaccination Syndrome (PACVS). Vaccines 12 (7), 790. https:\/\/doi.org\/10.3390\/vaccines12070790 (2024).","journal-title":"Vaccines"},{"key":"43949_CR17","doi-asserted-by":"publisher","first-page":"154497","DOI":"10.1016\/j.prp.2023.154497","volume":"246","author":"F Scholkmann","year":"2023","unstructured":"Scholkmann, F. & May, C. A. COVID-19, post-acute COVID-19 syndrome (PACS, long COVID) and post-COVID-19 vaccination syndrome (PCVS, post-COVIDvac-syndrome): Similarities and differences. Pathol. Res. Pract. 246, 154497. https:\/\/doi.org\/10.1016\/j.prp.2023.154497 (2023).","journal-title":"Pathol. Res. Pract."},{"key":"43949_CR18","unstructured":"Sample, I. People with Covid vaccine injuries not getting help they need, inquiry hears. The Guardian https:\/\/www.theguardian.com\/uk-news\/2025\/jan\/15\/people-with-covid-vaccine-injuries-not-getting-help-they-need-inquiry-hears. (2025)."},{"issue":"1","key":"43949_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.vacun.2023.10.002","volume":"25","author":"Y Shrestha","year":"2024","unstructured":"Shrestha, Y. & Venkataraman, R. The prevalence of post-COVID-19 vaccination syndrome and quality of life among COVID-19-vaccinated individuals. Vacunas 25 (1), 7\u201318. https:\/\/doi.org\/10.1016\/j.vacun.2023.10.002 (2024).","journal-title":"Vacunas"},{"issue":"12","key":"43949_CR20","doi-asserted-by":"publisher","first-page":"e27188","DOI":"10.2196\/27188","volume":"23","author":"E Chan","year":"2021","unstructured":"Chan, E. et al. The Utility of Different Data Standards to Document Adverse Drug Event Symptoms and Diagnoses: Mixed Methods Study. J. Med. Internet Res. 23 (12), e27188. https:\/\/doi.org\/10.2196\/27188 (2021).","journal-title":"J. Med. Internet Res."},{"issue":"4","key":"43949_CR21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/jamia\/ocy169","volume":"26","author":"AE Chung","year":"2019","unstructured":"Chung, A. E. et al. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute\u2019s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J. Am Med. Inf. Assoc. 26 (4), 276\u2013285. https:\/\/doi.org\/10.1093\/jamia\/ocy169 (2019).","journal-title":"J. Am Med. Inf. Assoc"},{"issue":"Suppl 4","key":"43949_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12911-023-02375-1","volume":"23","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. Evaluating MedDRA-to-ICD terminology mappings. BMC Med. Inf. Decis. Mak. 23 (Suppl 4), 299. https:\/\/doi.org\/10.1186\/s12911-023-02375-1 (2024).","journal-title":"BMC Med. Inf. Decis. Mak."},{"issue":"2","key":"43949_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown, E. G., Wood, L. & Wood, S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 20 (2), 109\u2013117. https:\/\/doi.org\/10.2165\/00002018-199920020-00002 (1999).","journal-title":"Drug Saf."},{"issue":"1159","key":"43949_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/postgradmedj-2021-140654","volume":"98","author":"AI Francis","year":"2022","unstructured":"Francis, A. I., Ghany, S., Gilkes, T. & Umakanthan, S. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgrad. Med. J. 98 (1159), 389\u2013394. https:\/\/doi.org\/10.1136\/postgradmedj-2021-140654 (2022).","journal-title":"Postgrad. Med. J."},{"issue":"1","key":"43949_CR25","doi-asserted-by":"publisher","first-page":"2002083","DOI":"10.1080\/21645515.2021.2002083","volume":"18","author":"R Patel","year":"2022","unstructured":"Patel, R., Kaki, M., Potluri, V. S., Kahar, P. & Khanna, D. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. Hum. Vaccin Immunother. 18 (1), 2002083. https:\/\/doi.org\/10.1080\/21645515.2021.2002083 (2022).","journal-title":"Hum. Vaccin Immunother"},{"issue":"8","key":"43949_CR26","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.3390\/biomedicines11082287","volume":"11","author":"PI Parry","year":"2023","unstructured":"Parry, P. I. et al. Spikeopathy\u2019: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA. Biomedicines 11 (8), 2287. https:\/\/doi.org\/10.3390\/biomedicines11082287 (2023).","journal-title":"Biomedicines"},{"key":"43949_CR27","doi-asserted-by":"publisher","unstructured":"Pateev, I., Seregina, K., Ivanov, R. & Reshetnikov, V. Biodistribution of RNA Vaccines and of Their Products: Evidence from Human and Animal Studies. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12010059 (2023).","DOI":"10.3390\/biomedicines12010059"},{"issue":"5","key":"43949_CR28","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3390\/v15051045","volume":"15","author":"CA Devaux","year":"2023","unstructured":"Devaux, C. A. & Camoin-Jau, L. Molecular Mimicry of the Viral Spike in the SARS-CoV-2 Vaccine Possibly Triggers Transient Dysregulation of ACE2, Leading to Vascular and Coagulation Dysfunction Similar to SARS-CoV-2 Infection. Viruses 15 (5), 1045. https:\/\/doi.org\/10.3390\/v15051045 (2023).","journal-title":"Viruses"},{"issue":"2","key":"43949_CR29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/biomedicines11020451","volume":"11","author":"P Bellavite","year":"2023","unstructured":"Bellavite, P., Ferraresi, A. & Isidoro, C. Immune Response and Molecular Mechanisms of Cardiovascular Adverse Effects of Spike Proteins from SARS-CoV-2 and mRNA Vaccines. Biomedicines 11 (2), 451. https:\/\/doi.org\/10.3390\/biomedicines11020451 (2023).","journal-title":"Biomedicines"},{"issue":"12","key":"43949_CR30","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.3390\/cells10123279","volume":"10","author":"D Barreda","year":"2021","unstructured":"Barreda, D. et al. SARS-CoV-2 Spike Protein and Its Receptor Binding Domain Promote a Proinflammatory Activation Profile on Human Dendritic Cells. Cells 10 (12), 3279. https:\/\/doi.org\/10.3390\/cells10123279 (2021).","journal-title":"Cells"},{"issue":"2","key":"43949_CR31","doi-asserted-by":"publisher","first-page":"e34872","DOI":"10.7759\/cureus.34872","volume":"15","author":"S Seneff","year":"2023","unstructured":"Seneff, S., Kyriakopoulos, A. M., Nigh, G. & McCullough, P. A. A Potential Role of the Spike Protein in Neurodegenerative Diseases: A Narrative Review. Cureus 15 (2), e34872. https:\/\/doi.org\/10.7759\/cureus.34872 (2023).","journal-title":"Cureus"},{"key":"43949_CR32","doi-asserted-by":"publisher","first-page":"111223","DOI":"10.1016\/j.jocn.2025.111223","volume":"136","author":"N Ota","year":"2025","unstructured":"Ota, N. et al. Expression of SARS-CoV-2 spike protein in cerebral Arteries: Implications for hemorrhagic stroke Post-mRNA vaccination. J. Clin. Neurosci. 136, 111223. https:\/\/doi.org\/10.1016\/j.jocn.2025.111223 (2025).","journal-title":"J. Clin. Neurosci."},{"issue":"12","key":"43949_CR33","doi-asserted-by":"publisher","first-page":"103479","DOI":"10.1016\/j.isci.2021.103479","volume":"24","author":"S Ndeupen","year":"2021","unstructured":"Ndeupen, S. et al. The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24 (12), 103479. https:\/\/doi.org\/10.1016\/j.isci.2021.103479 (2021).","journal-title":"iScience"},{"key":"43949_CR34","doi-asserted-by":"publisher","unstructured":"Wang, J. et al. Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery. Vaccines (Basel). https:\/\/doi.org\/10.3390\/vaccines12101148. (2024).","DOI":"10.3390\/vaccines12101148"},{"issue":"10","key":"43949_CR35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3390\/diseases12100231","volume":"12","author":"T Awaya","year":"2024","unstructured":"Awaya, T., Hara, H. & Moroi, M. Cytokine Storms and Anaphylaxis Following COVID-19 mRNA-LNP Vaccination: Mechanisms and Therapeutic Approaches. Diseases 12 (10), 231. https:\/\/doi.org\/10.3390\/diseases12100231 (2024).","journal-title":"Diseases"},{"issue":"10","key":"43949_CR36","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","volume":"55","author":"Y Lee","year":"2023","unstructured":"Lee, Y., Jeong, M., Park, J., Jung, H. & Lee, H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp. Mol. Med. 55 (10), 2085\u20132096. https:\/\/doi.org\/10.1038\/s12276-023-01086-x (2023).","journal-title":"Exp. Mol. Med."},{"key":"43949_CR37","doi-asserted-by":"publisher","first-page":"1336906","DOI":"10.3389\/fimmu.2024.1336906","volume":"15","author":"BZ Igy\u00e1rt\u00f3","year":"2024","unstructured":"Igy\u00e1rt\u00f3, B. Z. & Qin, Z. The mRNA-LNP vaccines - the good, the bad and the ugly? Front. Immunol. 15, 1336906. https:\/\/doi.org\/10.3389\/fimmu.2024.1336906 (2024).","journal-title":"Front. Immunol."},{"issue":"10","key":"43949_CR38","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/qjmed\/hcae103","volume":"117","author":"JH Roh","year":"2024","unstructured":"Roh, J. H., Jung, I., Suh, Y. & Kim, M. H. A potential association between COVID-19 vaccination and development of Alzheimer\u2019s disease. QJM 117 (10), 709\u2013716. https:\/\/doi.org\/10.1093\/qjmed\/hcae103 (2024).","journal-title":"QJM"},{"issue":"48","key":"43949_CR39","doi-asserted-by":"publisher","first-page":"eadd4150","DOI":"10.1126\/sciadv.add4150","volume":"8","author":"O Solis","year":"2022","unstructured":"Solis, O. et al. The SARS-CoV-2 spike protein binds and modulates estrogen receptors. Sci. Adv. 8 (48), eadd4150. https:\/\/doi.org\/10.1126\/sciadv.add4150 (2022).","journal-title":"Sci. Adv."},{"issue":"1","key":"43949_CR40","doi-asserted-by":"publisher","first-page":"2494934","DOI":"10.1080\/21645515.2025.2494934","volume":"21","author":"BK Patterson","year":"2025","unstructured":"Patterson, B. K. et al. Detection of S1 spike protein in CD16\u2009+\u2009monocytes up to 245 days in SARS-CoV-2-negative post-COVID-19 vaccine syndrome (PCVS) individuals. Hum. Vaccin Immunother. 21 (1), 2494934. https:\/\/doi.org\/10.1080\/21645515.2025.2494934 (2025).","journal-title":"Hum. Vaccin Immunother"},{"key":"43949_CR41","doi-asserted-by":"publisher","first-page":"112718","DOI":"10.1016\/j.nut.2025.112718","volume":"18","author":"S Kodama","year":"2025","unstructured":"Kodama, S. et al. Efficacy of Vitamin D Replacement Therapy on 28 Cases of Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome After COVID-19 Vaccination. Nutrition Published online Febr. 18, 112718. https:\/\/doi.org\/10.1016\/j.nut.2025.112718 (2025).","journal-title":"Nutrition Published online Febr."},{"key":"43949_CR42","doi-asserted-by":"publisher","unstructured":"Ruiz-Pablos, M., Paiva, B. & Zabaleta, A. Hypocortisolemic ASIA: a vaccine- and chronic infection-induced syndrome behind the origin of long COVID and myalgic encephalomyelitis. Front. Immunol. 15 https:\/\/doi.org\/10.3389\/fimmu.2024.1422940 (2024).","DOI":"10.3389\/fimmu.2024.1422940"},{"key":"43949_CR43","unstructured":"International Association for Chronic Fatigue Syndrome. \/ Myalgic Encephalomyelitis (IACFS\/ME).Chronic Fatigue Syndrome Myalgic Encephalomyelitis: A Primer for Clinical Practitioners 2014 Edition.https:\/\/www.iacfsme.org\/assets\/pdf\/Primer_Post_2014_conference\/. (2025)."},{"key":"43949_CR44","unstructured":"Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome, Board on the Health of Select Populations, Institute of Medicine. Beyond Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome: Redefining an Illness. National Academies Press (US). http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK274235\/ (2015)."},{"key":"43949_CR45","doi-asserted-by":"publisher","unstructured":"Wong, T. L. & Weitzer, D. J. Long COVID and Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome (ME\/CFS)\u2014A Systemic Review and Comparison of Clinical Presentation and Symptomatology. Medicina 57 (5). https:\/\/doi.org\/10.3390\/medicina57050418 (2021).","DOI":"10.3390\/medicina57050418"},{"key":"43949_CR46","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Adverse Event Report for COVID-19 Vaccines (up to 31 May 2025). 2025[in Japanese]. https:\/\/www.mhlw.go.jp\/stf\/shingi\/shingi-kousei_284075.html (2025)."},{"key":"43949_CR47","unstructured":"Ministry of Health, Labour and Welfare (MHLW). Statistics on the Immunisation Health-Damage Relief System 2025[in Japanese]. https:\/\/www.mhlw.go.jp\/stf\/shingi\/shingi-shippei_127696_00006.html, (2025)."},{"key":"43949_CR48","unstructured":"MHLW, Vaccination Office & Pharmaceutical Safety Division. Administrative communication on municipality management of suspected vaccine adverse reactions. 2023[in Japanese]. https:\/\/www.mhlw.go.jp\/content\/000735224.pdf. (2025)."},{"key":"43949_CR49","unstructured":"MHLW. Notification on the establishment of a medical consultation system for long-term adverse reactions after COVID-19 vaccination. [in Japanese]. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/vaccine_yuukousei_anzensei.html, (2022)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43949-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43949-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43949-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T14:20:20Z","timestamp":1776176420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43949-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["43949"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-43949-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12366"}}